GCAC to Participate in Medical Cannabis Study Conducted by University of British Columbia Professor, Dr. Alasdair Barr
Global Cannabis Applications Corp. (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF), a leading developer of innovative data technologies for the cannabis industry, is pleased to announce that it will participate in a medical cannabis study on the effects of cannabis on mental health conducted by Dr. Alasdair Barr.
GCAC will support Dr. Alasdair Barr, PhD, in a medical cannabis research study conducted by the University of British Columbia on the effects of cannabis on mental health. The study will be applied using semi-structured clinical interviews with instruments commonly applied to clinical trials in order to investigate a population of people in Vancouver, BC who suffer from mental health issues and choose to self-medicate with medical cannabis. By using clinical interviews and questionnaires, the results of the study are expected to gain a more thorough understanding of the population that uses medical cannabis, including the frequency and specific type of cannabis cultivars used for specific symptoms or disorders. Medical cannabis can be used for a wide variety of different medical conditions, but the large majority of patients use it for its psychological effects, such as for anxiety, depression, pain and insomnia.
Dr. Alasdair Barr is an Associate Professor at the University of British Columbia with a focus on mental health and addictions research, using a multidisciplinary and translational approach that spans from laboratory to clinic. Dr. Barr maintains active programs in both clinical and preclinical research and has been published in over 150 peer-reviewed articles. Dr. Barr is active in the cannabis space and serves as a scientific consultant to multiple cannabis based companies.
“I am happy that Global Cannabis is joining our efforts to provide further information about potentially better treatments for mental health” said Dr. Barr. “Mental illness will affect more than half of all Canadians during their lifetime. Traditionally, mental illness is treated with pharmacological drugs that can come with unwanted side effects. Many patients have therefore started looking for alternatives to “big pharma” medications, and in this search have found medical cannabis to be helpful. Though there is limited research supporting many of its benefits, the role of cannabis in mental health is still unclear and therefore requires further investigation, as many epidemiological studies obtain only superficial data about current mental health status.”
States GCAC CEO Brad Moore, “We are honoured to work with Dr. Barr in his invaluable work on studying the effects of medical cannabis on mental health. The results of this invaluable information will help provide clarity on the benefits of medical cannabis and will enhance the data on the Citizen Green technology platform and GCAC’s ‘Pain to Strain’ model.”
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, marketing, and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, reg tech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in medical cannabis. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.
To schedule an interview, please contact:
Chief Executive Officer
For more information, please contact:
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.